Andrew Bowler

Partner, Bristows
Andy has specialised in contentious intellectual property matters, including related advisory work, since qualification in 1999. His advice covers the full range of intellectual property rights, with a particular emphasis on patents, trademarks, registered designs and trade secrets.

Andy has considerable experience of representing high profile clients in cases in the UK High Court, the IP Enterprise Court and the Court of Appeal. He has also been responsible for opposition and cancellation proceedings in the UK IP Office, EPO and OHIM. Andy is regularly involved in the co-ordination of proceedings with parallel actions elsewhere in the EU and US and also has experience of litigation in China. He has conducted several successful mediations of IP disputes.
Andy advises clients across a wide range of technologies, including complex mechanical and FMCG products, mobile phones, pharmaceuticals, electronics and medical devices as well as music, films and other media.

Andy has recently assisted a leading consumer products company in successful trade mark proceedings before the CJEU. His recent patent litigation experience has included acting for Kennametal, a $2 billion per year NYSE company, in successfully defending patent infringement proceedings brought in the Patents Court in London by their biggest competitor (Sandvik v Kennametal [2011] EWHC 3311 (Pat)), and successfully representing Siemens and its customers in the same venue in relation to infringement proceedings in the field of wind turbine technology (Wobben Properties GmbH v Siemens PLC & Ors [2015] EWHC 2114 (Pat)).


He has been recommended in Chambers & Partners, Legal 500, the International Who’s Who of Patent Lawyers and Best Lawyer UK.
Contributed to

1

Second and subsequent medical use patent claims
Practice Note

This Practice Note examines the two different types of second medical use claims (purpose limited process ‘Swiss-form’ claims and purpose limited product ‘EPC 2000’ claims), the differences between them and their enforcement in England and Wales. It also discusses the impact of the Supreme Court judgment in Warner-Lambert v Generics (UK) and Actavis.

Practice areas

Panel

  • Consulting Editorial Board
  • Contributing Author

Education

  • University of Bristol: Diploma in IP Law & Practice
  • College of Law: CPE, LPC
  • University of Manchester: BA (Hons)

If you expected to see yourself on this page, click here.